نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

Journal: : 2023

Viral infections especially herpes virus and varicella zoster are common complications in patients with hematologic malignancies. The spectrum of infectious during after dasatinib therapy not known. I report here recurrent labialis two chronic myeloid leukemia cases treated dasatinib.

Journal: :Molecular cancer therapeutics 2010
Jonathan M Levitt Hideyuki Yamashita Weiguo Jian Seth P Lerner Guru Sonpavde

Dasatinib is an orally administered multitargeted kinase inhibitor that targets Src family tyrosine kinases, Abl, c-Kit, and PDGFR. A preclinical study was conducted to evaluate dasatinib alone or combined with cisplatin for human transitional cell carcinoma (TCC). Expression of Src in a human TCC tissue microarray was evaluated by immunohistochemistry. The activity of dasatinib and/or cisplati...

Journal: :Molecular cancer therapeutics 2009
Vanessa Milano Yuji Piao Tiffany LaFortune John de Groot

Glioblastoma is defined by its aggressive invasion, microvascular proliferation, and central necrosis. BMS-354825 (dasatinib) is an ATP-competitive small-molecule inhibitor effective in treating drug-resistant tumors with mutant BCR-ABL, KIT, and epidermal growth factor receptor by blocking tyrosine phosphorylation sites that are critical in tumorigenesis. In studying the action of dasatinib in...

2013
Yanfen Fang Like Zhong Meihua Lin Xinglu Zhou Hui Jing Meidan Ying Peihua Luo Bo Yang Qiaojun He

Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib. Here we report a novel effect of dasatinib on inducing the differentiation of acute myeloid leukemia (AML) cells through MEK/ERK-dependent activation of sig...

Journal: :Molecular cancer therapeutics 2007
Sangkil Nam Ann Williams Adina Vultur Alan List Kapil Bhalla David Smith Francis Y Lee Richard Jove

Dasatinib (BMS-354825) is a novel, oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases (SFK) and is a promising cancer therapeutic agent. Preclinical data indicate that dasatinib is 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl, and that dasatinib is active against 18 of 19 Bcr-Abl mutations known to cause imatinib resistance. Phase I ...

Journal: :Journal of proteomics 2011
Alex J Eustace Paul Dowling Michael Henry Padraig Doolan Paula Meleady Martin Clynes John Crown Norma O'Donovan

Current therapeutic regimes for metastatic melanoma have failed to provide robust clinical responses. Dasatinib has shown anti-proliferative and anti-invasive effects in vitro; however, not all melanoma cells tested were sensitive to dasatinib. We used 2D-DIGE analysis of phospho-enriched fractions to identify phosphoproteins involved in regulating response to dasatinib in an isogenic pair of m...

2014
Yu-Chin Lin Meng-Hsuan Wu Tzu-Tang Wei Yun-Chieh Lin Wen-Chih Huang Liang-Yu Huang Yi-Ting Lin Ching-Chow Chen

Head and neck squamous cell carcinoma (HNSCC) is an important endemic disease in Taiwan with aggressive course and dismal outcome. Dasatinib is a Bcr-bl and Src kinase inhibitor that has potential against HNSCC. We recently disclosed that EGFR degradation is critical for dasatinib-induced apoptosis. Here, we further demonstrate that AMPK-dependent ER stress is responsible for this event. Dasati...

Journal: :Cancer research 2014
Yun Bai Jae-Young Kim January M Watters Bin Fang Fumi Kinose Lanxi Song John M Koomen Jamie K Teer Kate Fisher Yian Ann Chen Uwe Rix Eric B Haura

DDR2 mutations occur in approximately 4% of lung squamous cell cancer (SCC) where the tyrosine kinase inhibitor dasatinib has emerged as a new therapeutic option. We found that ERK and AKT phosphorylation was weakly inhibited by dasatinib in DDR2-mutant lung SCC cells, suggesting that dasatinib inhibits survival signals distinct from other oncogenic receptor tyrosine kinases (RTK) and/or compen...

2015
Ji Hyung Hong Sung-Eun Lee Soo Young Choi Soo-Hyun Kim Eun-Jung Jang Ju-Hee Bang Jin Eok Park Hye-Rim Jeon Yun Jeong Oh Jeong-Eun Yi Hae Ok Jung Ho Joong Youn Dong-Wook Kim

We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with...

2014
Sook-Kyoung Heo Eui-Kyu Noh Dong-Joon Yoon Jae-Cheol Jo Jae-Hoo Park Hawk Kim

Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor. The aim of this research was to determine the anti-leukemic effects of dasatinib and VPA in combination and to identify their mechanism of act...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید